Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major

被引:41
作者
Buckner, FS [1 ]
Eastman, RT
Nepomuceno-Silva, JL
Speelmon, EC
Myler, PJ
Van Voorhis, WC
Yokoyama, K
机构
[1] Univ Washington, Dept Med, Seattle, WA 98195 USA
[2] Univ Washington, Dept Chem, Seattle, WA 98195 USA
[3] Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA
[4] Seattle Biomed Res Inst, Seattle, WA 98109 USA
关键词
protein prenylation; farnesylation; anti-parasitic agents; Trypanosama cruzi; Trypanosoma brucei; Leishmania major;
D O I
10.1016/S0166-6851(02)00099-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chagas disease and leishmaniasis Eire tropical diseases caused by the protozoan parasites, Trypanosoma cruzi and Leishmania species, respectively. Protein farnesyltransferase (PFT) is being investigated as a target for anti-trypanosomatid agents because inhibitors of this enzyme are highly toxic to these parasites compared to mammalian cells. Here, we report the cloning of the alpha- and beta-subunit genes of PFT from T. cruzi and Leishmania major. The proteins encoded by these genes are considerably larger than those of mammalian PFTs due to the presence of a number of inserts of > 25 amino acids that map to junctions between helical structural elements. These inserts are not part of the active site or the interface between the two subunits, Northern blots demonstrate expression of messenger RNA for the PFT subunits in both mammalian and insect life-cycle stages of these parasites. The T cruzi Trypanosoma brucei, and L. major PFTs were overexpressed in the Sf9 cell/baculovirus system as active enzyme forms. Kinetic studies with a panel of CALX-containing peptides with all 20 amino acids in the X-position show that trypanosomatid PFTs have similar substrate specificities and these are different from the mammalian PFT substrate specificity patterns. (C) 2002 Elsevier Science B.V, All rights reserved.
引用
收藏
页码:181 / 188
页数:8
相关论文
共 26 条
[1]   Blocking oncogenic Ras signaling for cancer therapy [J].
Adjei, AA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (14) :1062-1074
[2]  
BUCKNER FS, 2000, J BIOL CHEM, V29, P28170
[3]   Protein prenyl transferase activities of Plasmodium falciparum [J].
Chakrabarti, D ;
Azam, T ;
DelVecchio, C ;
Qiu, LB ;
Park, Y ;
Allen, CM .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 1998, 94 (02) :175-184
[4]   Farnesyltransferase inhibitors - Potential role in the treatment of cancer [J].
Cox, AD .
DRUGS, 2001, 61 (06) :723-732
[5]  
DelVillar K, 1997, J BIOL CHEM, V272, P680
[6]   Protein isoprenylation in Trypanosoma brucei brucei. [J].
Field, H ;
Blench, I ;
Croft, S ;
Field, MC .
BIOCHEMICAL SOCIETY TRANSACTIONS, 1996, 24 (03) :S433-S433
[7]   ROLE OF PROTEIN MODIFICATION REACTIONS IN PROGRAMMING INTERACTIONS BETWEEN RAS-RELATED GTPASES AND CELL-MEMBRANES [J].
GLOMSET, JA ;
FARNSWORTH, CC .
ANNUAL REVIEW OF CELL BIOLOGY, 1994, 10 :181-205
[8]   A physical map of the Leishmania major Friedlin genome [J].
Ivens, AC ;
Lewis, SM ;
Bagherzadeh, A ;
Zhang, L ;
Chan, HM ;
Smith, DF .
GENOME RESEARCH, 1998, 8 (02) :135-145
[9]   Current status of clinical trials of farnesyltransferase inhibitors [J].
Karp, JE ;
Kaufmann, SH ;
Adjei, AA ;
Lancet, JE ;
Wright, JJ ;
End, DW .
CURRENT OPINION IN ONCOLOGY, 2001, 13 (06) :470-476
[10]   Ras farnesyltransferase: A new therapeutic target [J].
Leonard, DM .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (19) :2971-2990